The most noteworthy aspect of the US Food & Drug Administration’s 13 May hearing on the pathway for biosimilar insulin may have been the very limited number of sponsors who chose to present.
Of the three largest suppliers of insulin in the US, only Eli Lilly & Co. made a formal statement...